3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Tumor-Agnostic
1
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
32
Neoplasm Metastasis
6
Metastatic Castration-resistant Prostate Cancer
3
Urogenital Neoplasms
1
Prostate Cancer Metastatic
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Castration-Resistant Prostate Cancer Patients
1
Metastatic Castration-Resistant Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Abiraterone Acetate
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
15
Paclitaxel
13
Prednisone
12
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
atezolizumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
enzalutamide
5
cemiplimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Prednisolone
×
Genitourinary
×
Clear all
NCT00519285
2016-07-22
VENICE
Sanofi
Phase 3
Completed
1,224 enrolled
21 charts